Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Acumen Pharmaceuticals is scheduled to report Q1 2026 results before the market opens on May 12, 2026, with analysts projecting EPS of ($0.4028) per share.
• In the prior quarter (reported Mar. 26) Acumen posted EPS of ($0.41), beating consensus of ($0.50) by $0.09 while reporting about ($0.09) million in revenue.
• Analysts have a consensus rating of "Moderate Buy" with an average price target of $6.67, and institutional investors own roughly 71.01% of the shares.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.4028) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last issued its earnings results on Thursday, March 26th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.09. The business had revenue of ($0.09) million during the quarter.

Acumen Pharmaceuticals Stock Performance

NASDAQ:ABOS traded up $0.01 during mid-day trading on Tuesday, reaching $2.49. The company's stock had a trading volume of 62,895 shares, compared to its average volume of 716,967. Acumen Pharmaceuticals has a 12-month low of $0.96 and a 12-month high of $3.60. The firm's fifty day moving average price is $2.79 and its two-hundred day moving average price is $2.33. The company has a current ratio of 4.07, a quick ratio of 4.07 and a debt-to-equity ratio of 0.32. The stock has a market cap of $179.49 million, a P/E ratio of -1.23 and a beta of 0.32.

Analysts Set New Price Targets

A number of equities analysts have weighed in on ABOS shares. Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, March 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a research report on Wednesday, April 8th. Finally, BTIG Research reaffirmed a "buy" rating and set a $8.00 price target on shares of Acumen Pharmaceuticals in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Acumen Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $6.67.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ABOS. AQR Capital Management LLC purchased a new stake in shares of Acumen Pharmaceuticals during the 1st quarter valued at about $46,000. Marshall Wace LLP purchased a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter valued at about $160,000. Qube Research & Technologies Ltd increased its position in shares of Acumen Pharmaceuticals by 160.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company's stock valued at $67,000 after purchasing an additional 35,424 shares during the last quarter. Jane Street Group LLC increased its position in shares of Acumen Pharmaceuticals by 1,526.0% during the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company's stock valued at $204,000 after purchasing an additional 164,866 shares during the last quarter. Finally, Hudson Bay Capital Management LP increased its holdings in Acumen Pharmaceuticals by 7.1% in the 2nd quarter. Hudson Bay Capital Management LP now owns 825,004 shares of the company's stock worth $957,000 after acquiring an additional 55,004 shares in the last quarter. Hedge funds and other institutional investors own 71.01% of the company's stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.

The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.